Index: 10.1038/nrd.2018.41
Full Text: HTML
George Yancopoulos George Yancopoulos, Published online: 28 March 2018; doi:10.1038/nrd.2018.41George Yancopoulos, CSO of Regeneron, discusses his 30 years at Regeneron, the company's evolving growth plans and the recent launch of a precompetitive collaboration to sequence 500,000 UK Biobank exomes.
INFORMED: an incubator at the US FDA for driving innovations...
2018-04-06 [10.1038/nrd.2018.34] |
The gastroesophageal cancer drug market
2018-04-03 [10.1038/nrd.2018.35] |
Antivirals: Topical therapy for ocular herpes
2018-03-28 [10.1038/nrd.2018.47] |
Infectious disease: Virus-based tuberculosis vaccine
2018-03-28 [10.1038/nrd.2018.50] |
Immunotherapy: iPSC-based cancer vaccine
2018-03-28 [10.1038/nrd.2018.48] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved